Details

Autor(en) / Beteiligte

• Melissa K. Lingohr
• Isabelle Briaud
• Lorna M. Dickson
• Jill F. McCuaig
• Cristina Alárcon
• Barton L. Wicksteed
• Christopher J. Rhodes

Titel

Specific Regulation of IRS-2 Expression by Glucose in Rat Primary Pancreatic Islet β-Cells

Ist Teil von

• The Journal of biological chemistry, 2006-06, Vol.281 (23), p.15884

Ort / Verlag

American Society for Biochemistry and Molecular Biology

Erscheinungsjahr

2006

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Insulin receptor substrate 2 (IRS-2) plays a critical role in pancreatic β-cells. Increased IRS-2 expression promotes β-cell growth and survival, whereas decreased IRS-2 levels lead to apoptosis. It was found that IRS-2 turnover in rat islet β-cells was rapid, with mRNA and protein half-lives of ∼90 min and ∼2 h, respectively. However, this was countered by specific glucose-regulated IRS-2 expression mediated at the transcriptional level. Glucose (≥6 m m ) increased IRS-2 mRNA and protein levels in a dose-dependent manner, reaching a maximum 4-fold increase in IRS-2 mRNA and a 5–6-fold increase in IRS-2 protein levels at ≥12 m m glucose ( p ≤ 0.01). Glucose (15 m m ) regulation of islet β-cell IRS-2 gene expression was rapid, with a significant increase in IRS-2 mRNA levels within 2 h that reached a maximum 4-fold increase by 4 h. IRS-2 protein expression in β-cells followed that of IRS-2 mRNA. Glucose metabolism was necessary for increased IRS-2 expression in β-cells. Moreover, inhibition of a glucose-induced rise in islet β-cell cytosolic [Ca 2+ ] i prevented an increase in IRS-2 expression, indicating this was Ca 2+ -dependent. The glucose-induced rise in IRS-2 levels correlated with increased IRS-2 tyrosine phosphorylation and downstream activation of protein kinase B. These data indicate that fluctuations of glucose in the normal physiological range (5–15 m m ) promote β-cell survival via regulation of IRS-2 expression and a subsequent parallel protein kinase B activation. Given that the onset of type-2 diabetes is marked by loss of β-cells, these data further the idea that controlled IRS-2 expression in β-cells could be a therapeutic means to promote β-cell survival and delay the onset of the disease.